Athersys
Founded Year
1995Stage
Corporate Minority | AliveTotal Raised
$100.41MValuation
$0000Last Raised
$7.04M | 3 yrs agoRevenue
$0000Missing: Athersys's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Athersys's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Athersys
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Athersys is included in 2 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Athersys Patents
Athersys has filed 17 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immune system
- Immunology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/20/2017 | 6/7/2022 | Stem cells, Developmental biology, Transcription factors, Embryology, Biotechnology | Grant |
Application Date | 12/20/2017 |
|---|---|
Grant Date | 6/7/2022 |
Title | |
Related Topics | Stem cells, Developmental biology, Transcription factors, Embryology, Biotechnology |
Status | Grant |
Latest Athersys News
May 23, 2023
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier (“the supplier”). The Company previously entered into agreements with the supplier to assist in the scale-up and manufacturing of clinical and commercial grade MultiStem® using Athersys’ bioreactor production processes. Under the new agreement, Athersys will p
Athersys Frequently Asked Questions (FAQ)
When was Athersys founded?
Athersys was founded in 1995.
Where is Athersys's headquarters?
Athersys's headquarters is located at 3201 Carnegie Avenue, Cleveland.
What is Athersys's latest funding round?
Athersys's latest funding round is Corporate Minority.
How much did Athersys raise?
Athersys raised a total of $100.41M.
Who are the investors of Athersys?
Investors of Athersys include Healios K.K., Radius Ventures, Pappas Ventures, Tekla Capital Management, Accipiter Capital Management and 34 more.
Who are Athersys's competitors?
Competitors of Athersys include Affibody, Elusys Therapeutics, Amniotics, GangaGen, Regado Biosciences and 12 more.
Compare Athersys to Competitors
Alice Therapeutics is a biotechnology company.
Altair Therapeutics is a biotechnology company focused on the discovery, development and commercialization of antisense drugs for respiratory conditions.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
Pulmotect develops host-directed or pathogen-agnostic products to reduce morbidity and mortality in patients at risk of severe respiratory diseases. It offers immunomodulatory and pathogen-agnostic approaches to prevent and treat respiratory complications. The company was founded in 2007 and is based in Houston, Texas.
LeukoSight Inc. is an early stage biotechnology company developing a line of therapeutics that can be used to treat autoimmune and inflammatory diseases.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.